Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) announced Thursday that it and partner Medicom Healthcare Ltd have been issued a new Medical Device License for the second of three product submissions made for the Evolve preservative-free, dry eye product line.
In a statement, Aequus said that the license was issued for Evolve Daily Intensive – an advanced formulation of 0.2% Hyaluronate, free of preservatives and phosphates, and made available in a multi-dose bottle for ease of use for all patients. The formulation contains 350 drops that can be dispensed with gentle squeezing – an important feature for chronic users and many dry eye patients.
“Evolve Daily Intensive is the second lubricating eye drop being offered by Aequus as part of a full line of products made exclusive to Eye Care Professionals,” said Grant Larsen, chief commercial officer at Aequus.
READ: Aequus and partner Medicom Healthcare win Medical Device License for Evolve Intensive Gel to treat Dry Eye Disease
Aequus CEO Doug Janzen noted that “these Hyaluronate drops, in particular, are seen as the workhorse of the entire line, and are currently the fastest-growing Hyaluronate drops in the UK. The full range is expected to generate $10M a year in Canadian sales at maturity.”
Aequus said it is advancing launch activities for the newly approved Evolve products, while a third drop in the Evolve range is currently under review with Health Canada.
Dry eye disease (DED) is a common disorder of the tear film that leads to ocular surface damage over time. Previous research has shown DED reduces health and vision-related quality of life and that it carries a considerable economic burden of disease. DED affects about 6.3 million Canadians.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham
